AVITA Medical Reports Q3 Revenue Growth, Raises 2026 Guidance
AVITA Medical reported third-quarter revenue of $26.1 million, up 53% year over year and 20% sequentially. It raised full-year revenue guidance to $92 million-$94 million from $86 million-$89 million and reaffirmed its Q4 2026 cash flow breakeven expectation.
AVITA Medical announced its financial results for the third quarter ended September 30, 2026, reporting total revenue of $26.1 million, a 53% increase year-over-year and 20% sequentially. The company's gross margin improved to 84.0%, up 270 basis points from the prior-year period, driven by RECELL growth and manufacturing efficiencies. Net loss for the quarter was $6.2 million, or $0.20 per share, compared to a $13.2 million loss in the same period last year. Based on these results, the company raised its full-year 2026 revenue guidance to a range of $92 million to $94 million, up from its previous outlook of $86 million to $89 million.
Management reaffirmed its expectation to achieve cash flow breakeven in the fourth quarter of 2026.